VRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.20%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $120,441,655.39

Vertex Pharmaceuticals Insider Trading History Chart

Vertex Pharmaceuticals Share Price & Price History

^$516.34

▲ +3.08 (0.60%)

As of 09/17/2026 04:00 PM ET

Days: 30 | 90 | 365

Vertex Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/2/2026	Duncan McKechnie	EVP	Sell	1,541	$519.00	$799,779.00	11,001
7/2/2026	Ourania Tatsis	EVP	Sell	1,500	$524.99	$787,485.00	45,321
6/26/2026	Carmen Bozic	CMO	Sell	596	$482.50	$287,570.00	15,337
6/18/2026	Carmen Bozic	CMO	Sell	1,020	$462.17	$471,413.40	15,933
6/15/2026	Carmen Bozic	CMO	Sell	4,062	$450.00	$1,827,900.00	16,953
6/5/2026	Carmen Bozic	CMO	Sell	1,745	$450.00	$785,250.00	21,015
5/12/2026	Carmen Bozic	CMO	Sell	6,988	$450.00	$3,144,600.00	26,088
5/4/2026	Sangeeta N Bhatia	Director	Sell	318	$423.73	$134,746.14	4,924
5/1/2026	Joy Liu	EVP	Sell	1,104	$425.02	$469,222.08	20,729
4/1/2026	Joy Liu	EVP	Sell	978	$449.17	$439,288.26	21,833
3/13/2026	Carmen Bozic	CMO	Sell	2,329	$481.79	$1,122,088.91	35,405
2/25/2026	Amit Sachdev	EVP	Sell	1,846	$486.35	$897,802.10	55,570
2/25/2026	Duncan McKechnie	EVP	Sell	4,910	$487.65	$2,394,361.50	17,559
2/25/2026	E. Morrey Atkinson, III	EVP	Sell	668	$486.35	$324,881.80	18,432
2/25/2026	Jonathan Biller	EVP	Sell	945	$486.35	$459,600.75	13,659
2/25/2026	Kristen Ambrose	CAO	Sell	223	$486.35	$108,456.05	6,981
2/25/2026	Mark E. Bunnage	EVP	Sell	620	$486.35	$301,537.00	7,284
2/25/2026	Ourania Tatsis	EVP	Sell	260	$486.35	$126,451.00	46,763
2/19/2026	Amit Sachdev	EVP	Sell	58,613	$468.83	$27,479,532.79	58,934
2/13/2026	Ourania Tatsis	EVP	Sell	1,500	$499.99	$749,985.00	46,132
2/11/2026	E. Morrey Atkinson, III	EVP	Sell	1,751	$460.43	$806,212.93	22,046
2/11/2026	Jonathan Biller	EVP	Sell	1,925	$460.43	$886,327.75	20,819
2/11/2026	Kristen Ambrose	CAO	Sell	1,376	$460.43	$633,551.68	10,127
2/11/2026	Mark E. Bunnage	EVP	Sell	2,021	$460.43	$930,529.03	12,914
2/11/2026	Ourania Tatsis	EVP	Sell	466	$460.43	$214,560.38	51,436
1/7/2026	Ourania Tatsis	EVP	Sell	4,500	$474.99	$2,137,455.00	42,293
1/6/2026	Charles F. Wagner, Jr.	EVP	Sell	9,532	$461.00	$4,394,252.00	37,725
12/3/2025	Charles F. Wagner, Jr.	EVP	Sell	14,000	$456.00	$6,384,000.00	37,725
12/3/2025	Jeffrey M. Leiden	Chairman	Sell	63,781	$449.20	$28,650,425.20	24,026
11/14/2025	Jeffrey M. Leiden	Chairman	Sell	53,604	$440.72	$23,624,354.88	24,026
11/13/2025	Jeffrey M. Leiden	Chairman	Sell	19,688	$440.27	$8,668,035.76	24,026
8/6/2025	Bruce I. Sachs	Director	Buy	5,000	$389.68	$1,948,400.00	45,000
5/15/2025	David Altshuler	EVP	Sell	52	$424.69	$22,083.88	23,281
3/10/2025	David Altshuler	EVP	Sell	3,231	$500.00	$1,615,500.00	26,512
2/27/2025	Ourania Tatsis	EVP	Sell	530	$475.34	$251,930.20	58,539
2/18/2025	Ourania Tatsis	EVP	Sell	244	$455.06	$111,034.64	67,695
2/11/2025	Ourania Tatsis	EVP	Sell	310	$459.83	$142,547.30	64,021
11/15/2024	David Altshuler	EVP	Sell	15	$478.56	$7,178.40	25,813
8/30/2024	Jeffrey M. Leiden	Chairman	Sell	3,784	$499.00	$1,888,216.00	9,994
8/30/2024	Sangeeta N Bhatia	Director	Sell	646	$500.00	$323,000.00	4,435
8/7/2024	Carmen Bozic	CMO	Sell	2,280	$476.75	$1,086,990.00	23,259
8/1/2024	Bruce I. Sachs	Director	Sell	5,295	$508.00	$2,689,860.00	40,000
7/24/2024	Carmen Bozic	CMO	Sell	2,280	$488.46	$1,113,688.80	25,539
7/22/2024	Reshma Kewalramani	CEO	Sell	15,202	$497.00	$7,555,394.00	106,172
7/10/2024	Carmen Bozic	CMO	Sell	2,280	$487.34	$1,111,135.20	27,819
6/26/2024	Carmen Bozic	CMO	Sell	2,280	$471.72	$1,075,521.60	30,099
6/12/2024	Carmen Bozic	CMO	Sell	2,280	$478.00	$1,089,840.00	32,379
6/12/2024	E. Morrey Atkinson, III	EVP	Sell	7,288	$478.00	$3,483,664.00	15,972
5/30/2024	Ourania Tatsis	EVP	Sell	2,350	$439.11	$1,031,908.50	53,523
5/29/2024	Carmen Bozic	CMO	Sell	2,280	$445.56	$1,015,876.80	34,659
5/28/2024	Charles F. Wagner, Jr.	CFO	Sell	3,250	$454.79	$1,478,067.50	50,387
5/24/2024	Reshma Kewalramani	CEO	Sell	1,565	$457.00	$715,205.00	121,374
5/22/2024	Bruce I. Sachs	Director	Sell	7,073	$448.00	$3,168,704.00	40,000
2/26/2024	Ourania Tatsis	EVP	Sell	354	$425.70	$150,697.80	55,804
2/20/2024	Ourania Tatsis	EVP	Sell	480	$420.79	$201,979.20	59,827
2/12/2024	Amit Sachdev	EVP	Sell	3,222	$420.24	$1,354,013.28	74,364
2/12/2024	Jeffrey M. Leiden	Chairman	Sell	2,656	$419.51	$1,114,218.56	27,644
2/12/2024	Kristen Ambrose	CAO	Sell	1,374	$420.24	$577,409.76	9,676
2/12/2024	Stuart A. Arbuckle	COO	Sell	4,295	$420.24	$1,804,930.80	75,718
1/8/2024	Jeffrey M. Leiden	Chairman	Sell	6,648	$419.07	$2,785,977.36	2,423
11/6/2023	Bruce I. Sachs	Director	Sell	11,250	$385.00	$4,331,250.00	40,000
10/31/2023	Carmen Bozic	CMO	Sell	5,651	$355.92	$2,011,303.92	34,952
10/17/2023	Carmen Bozic	CMO	Sell	5,651	$373.25	$2,109,235.75	40,603
10/17/2023	Sangeeta N Bhatia	Director	Sell	243	$375.00	$91,125.00	3,901
10/16/2023	Jeffrey M. Leiden	Chairman	Sell	12,962	$374.00	$4,847,788.00	22,425
10/6/2023	Sangeeta N Bhatia	Director	Sell	242	$360.00	$87,120.00	4,144
10/3/2023	Carmen Bozic	CMO	Sell	5,651	$345.28	$1,951,177.28	46,254
10/2/2023	Jonathan Biller	EVP	Sell	610	$346.76	$211,523.60	10,569
9/19/2023	Carmen Bozic	CMO	Sell	5,651	$351.00	$1,983,501.00	51,905

SEC Filings (Institutional Ownership Changes) for Vertex Pharmaceuticals (NASDAQ:VRTX)

90.96% of Vertex Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vertex Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
9/9/2026	Capstone Financial Advisors Inc.	432	$0.22M	0.0%	N/A	0.000%
9/9/2026	Sequoia Financial Advisors LLC	16,729	$8.31M	0.0%	+12.3%	0.007%
9/9/2026	Tidal Investments LLC	95,685	$47.53M	0.1%	+3.9%	0.038%
9/9/2026	IPG Investment Advisors LLC	4,339	$2.16M	0.3%	+23.9%	0.002%
9/9/2026	MCF Advisors LLC	451	$0.22M	0.0%	+128.9%	0.000%
9/9/2026	National Pension Service	539,530	$268M	0.2%	+1.4%	0.213%
9/9/2026	Engineers Gate Manager LP	3,066	$1.52M	0.0%	-77.8%	0.001%
9/9/2026	Cidel Asset Management Inc.	766	$0.38M	0.0%	+12.8%	0.000%
9/9/2026	SVB Wealth LLC	1,123	$0.56M	0.0%	-60.5%	0.000%
9/9/2026	Pinnacle Wealth Management Advisory Group LLC	1,248	$0.62M	0.0%	+42.8%	0.000%
9/9/2026	NorthRock Partners LLC	1,113	$0.55M	0.0%	+3.2%	0.000%
9/9/2026	Integrated Wealth Concepts LLC	5,917	$2.94M	0.0%	+26.8%	0.002%
9/9/2026	Community Bank N.A.	500	$0.25M	0.0%	-43.2%	0.000%
9/9/2026	RFG Advisory LLC	1,989	$0.99M	0.0%	+19.5%	0.001%
9/9/2026	NewEdge Advisors LLC	18,435	$9.16M	0.0%	+7.5%	0.007%
9/9/2026	Hedeker Wealth LLC	7,515	$3.73M	0.7%	-1.5%	0.003%
9/9/2026	IFP Advisors Inc	2,968	$1.47M	0.0%	+9.1%	0.001%
9/9/2026	Baird Financial Group Inc.	4,126	$2.05M	0.0%	-53.0%	0.002%
9/9/2026	XY Planning Network Inc.	751	$0.37M	0.0%	N/A	0.000%
9/8/2026	Hudock Inc.	470	$0.23M	0.0%	N/A	0.000%
9/8/2026	Allworth Financial LP	4,487	$2.23M	0.0%	-71.6%	0.002%
9/8/2026	Arizona State Retirement System	70,580	$35.06M	0.2%	+1.5%	0.028%
9/8/2026	West Family Investments Inc.	1,695	$0.84M	0.2%	+33.0%	0.001%
9/8/2026	Waverly Advisors LLC	23,131	$11.49M	0.1%	+0.3%	0.009%
9/8/2026	Carmignac Gestion	163,045	$81M	1.0%	+10.0%	0.064%
9/8/2026	Lipe & Dalton	3,761	$1.87M	0.9%	-5.9%	0.001%
9/8/2026	Empirical Finance LLC	8,986	$4.46M	0.2%	+3.4%	0.004%
9/8/2026	Nykredit A S	204,386	$101.53M	0.3%	N/A	0.081%
9/4/2026	Parkside Financial Bank & Trust	759	$0.38M	0.0%	+3.3%	0.000%
9/2/2026	Second Line Capital LLC	1,125	$0.56M	0.1%	-5.4%	0.000%
9/2/2026	Range Advisory LLC	546	$0.27M	0.0%	N/A	0.000%
8/28/2026	Cornerstone Financial Management LLC	209	$0.10M	0.1%	+13.6%	0.000%
8/27/2026	Corient Private Wealth LP	103,755	$51.54M	0.1%	+20.0%	0.041%
8/27/2026	Formuepleje A S	2,409	$1.20M	0.1%	N/A	0.001%
8/26/2026	Amundi	1,546,509	$768.20M	0.2%	+5.0%	0.609%
8/26/2026	HighTower Advisors LLC	49,020	$24.35M	0.0%	-25.4%	0.019%
8/25/2026	Advus Financial Partners LLC	403	$0.20M	0.0%	N/A	0.000%
8/25/2026	VIRGINIA RETIREMENT SYSTEMS ET Al	94,060	$46.72M	0.3%	N/A	0.037%
8/23/2026	Ameritas Advisory Services LLC	337	$0.17M	0.0%	-72.3%	0.000%
8/23/2026	Wedmont Private Capital	3,524	$1.71M	0.0%	+4.2%	0.001%
8/23/2026	Kintra Wealth LLC	1,294	$0.67M	0.0%	-15.7%	0.001%
8/23/2026	Figure 8 Investment Strategies LLC	1,776	$0.88M	0.8%	+15.9%	0.001%
8/23/2026	HB Wealth Management LLC	11,065	$5.50M	0.0%	+7.6%	0.004%
8/23/2026	Nilsine Partners LLC	3,532	$1.75M	0.1%	-1.2%	0.001%
8/23/2026	Saudi Central Bank	17,805	$8.84M	0.1%	+90.1%	0.007%
8/23/2026	Fortitude Advisory Group L.L.C.	517	$0.26M	0.1%	N/A	0.000%
8/23/2026	Angeles Wealth Management LLC	1,409	$0.70M	0.0%	+2.4%	0.001%
8/23/2026	Azimuth Capital Investment Management LLC	17,818	$8.85M	0.3%	-4.5%	0.007%
8/22/2026	Compass Financial Management LLC	102	$49K	0.0%	N/A	0.000%
8/22/2026	MW Advisory LLC	878	$0.44M	0.2%	N/A	0.000%
8/22/2026	Strive Financial Group LLC	525	$0.26M	0.1%	+303.8%	0.000%
8/22/2026	Syon Capital LLC	3,640	$1.81M	0.1%	+2.2%	0.001%
8/22/2026	TD Waterhouse Canada Inc.	13,646	$6.80M	0.0%	-0.9%	0.005%
8/22/2026	Premier Path Wealth Partners LLC	1,751	$0.87M	0.1%	-6.4%	0.001%
8/22/2026	Barlow Wealth Partners LLC	30,786	$15.35M	1.6%	+1.2%	0.012%
8/22/2026	Concurrent Investment Advisors LLC	10,145	$5.04M	0.0%	+7.0%	0.004%
8/22/2026	NEOS Investment Management LLC	193,306	$96.02M	0.4%	+11.0%	0.076%
8/21/2026	AXQ Capital LP	2,797	$1.39M	0.2%	N/A	0.001%
8/21/2026	iSAM Funds UK Ltd	2,080	$1.03M	0.7%	+177.3%	0.001%
8/21/2026	Paragon Private Wealth Management LLC	467	$0.23M	0.1%	-3.9%	0.000%
8/21/2026	Continuum Advisory LLC	665	$0.33M	0.0%	-2.9%	0.000%
8/21/2026	Nykredit A S	248,068	$123.22M	0.4%	N/A	0.098%
8/21/2026	Coppell Advisory Solutions LLC	436	$0.22M	0.0%	N/A	0.000%
8/21/2026	Natural Investments LLC	1,294	$0.64M	0.1%	+2.3%	0.001%
8/21/2026	Tsfg LLC	151	$75K	0.0%	+41.1%	0.000%
8/21/2026	Symphony Financial Ltd. Co.	738	$0.37M	0.0%	+20.0%	0.000%
8/21/2026	Secure Asset Management LLC	411	$0.20M	0.0%	N/A	0.000%
8/21/2026	Independence Bank of Kentucky	4,504	$2.24M	0.3%	+405.5%	0.002%
8/21/2026	Midwest Professional Planners LTD.	3,471	$1.72M	0.3%	-2.2%	0.001%
8/21/2026	Triumph Capital Management	112	$56K	0.0%	-14.5%	0.000%
8/20/2026	Proficio Capital Partners LLC	2,184	$1.09M	0.0%	N/A	0.001%
8/20/2026	Nwam LLC	10,129	$5.03M	0.3%	+60.0%	0.004%
8/20/2026	Rehmann Capital Advisory Group	1,846	$0.92M	0.0%	-9.5%	0.001%
8/20/2026	Strategic Advisors LLC	812	$0.40M	0.1%	-90.2%	0.000%
8/20/2026	CTC Alternative Strategies Ltd.	1,760	$0.87M	1.3%	N/A	0.001%
8/20/2026	Oarsman Capital Inc.	5,101	$2.53M	0.2%	+2.4%	0.002%
8/20/2026	Quantitative Investment Management LLC	8,342	$4.14M	0.5%	N/A	0.003%
8/20/2026	Ancora Advisors LLC	1,127	$0.56M	0.0%	+7.3%	0.000%
8/20/2026	Sigma Planning Corp	1,033	$0.51M	0.0%	-2.7%	0.000%
8/20/2026	Two Sigma Securities LLC	923	$0.46M	0.0%	+57.2%	0.000%
8/20/2026	Benjamin Edwards Inc.	11,025	$5.48M	0.0%	-0.8%	0.004%
8/20/2026	GTS Securities LLC	1,060	$0.53M	0.0%	-39.0%	0.000%
8/20/2026	Flputnam Investment Management Co.	40,116	$19.93M	0.2%	+1.6%	0.016%
8/20/2026	Northwestern Mutual Wealth Management Co.	9,613	$4.78M	0.0%	+8.5%	0.004%
8/20/2026	Wedbush Securities Inc.	4,745	$2.36M	0.1%	-12.4%	0.002%
8/20/2026	Meiji Yasuda Life Insurance Co	4,673	$2.32M	0.1%	-6.6%	0.002%
8/20/2026	Greenwood Capital Associates LLC	12,024	$5.97M	0.6%	-0.6%	0.005%
8/20/2026	Greenleaf Trust	4,995	$2.48M	0.0%	+5.1%	0.002%
8/19/2026	Trustmark Bank Trust Department	4,021	$2M	0.1%	-4.0%	0.002%
8/19/2026	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	3,086,683	$1.53B	0.3%	+1.0%	1.216%
8/19/2026	Washington Trust Bank	21,320	$10.59M	0.7%	-14.5%	0.008%
8/19/2026	New Mexico Educational Retirement Board	12,700	$6.31M	0.2%	+8.5%	0.005%
8/19/2026	Royal London Asset Management Ltd.	241,280	$119.85M	0.2%	-4.3%	0.095%
8/19/2026	Mufg Securities Americas Inc.	7,645	$3.80M	0.2%	+8.8%	0.003%
8/19/2026	Van ECK Associates Corp	143,881	$71.47M	0.0%	-1.5%	0.057%
8/19/2026	Nissay Asset Management Corp Japan	75,743	$37.62M	0.2%	+6.0%	0.030%
8/19/2026	Hsbc Holdings PLC	676,247	$335.81M	0.1%	+3.2%	0.266%
8/19/2026	Wellington Management Group LLP	3,247,658	$1.61B	0.3%	+1.1%	1.280%
8/19/2026	Fox Hill Wealth Management	629	$0.31M	0.1%	N/A	0.000%
8/19/2026	Kingsview Wealth Management LLC	464	$0.23M	0.0%	N/A	0.000%

Data available starting January 2016

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $516.34

$510.20

$519.07

50 Day Range

MA: $511.35

$470.72

$557.96

52 Week Range

Now: $516.34

$374.17

$560.25

Volume

899,601 shs

Average Volume

879,500 shs

Market Capitalization

$131.05 billion

P/E Ratio

30.05

Dividend Yield

N/A

Beta

0.32

Who are the company insiders with the largest holdings of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top insider shareholders include:
Jeffrey M Leiden (CEO)
Joshua S Boger (Director)
Joshua Boger (Director)
Joshua S Boger (Director)
Jeffrey M Leiden (CEO)
Jeffrey Leiden (CEO)
Peter Mueller (EVP)
Ian F Smith (CFO)
Stuart A Arbuckle (EVP)
Jeffrey Chodakewitz (CMO)
Learn More about top insider investors at Vertex Pharmaceuticals.
Who are the major institutional investors of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top institutional investors include:
BlackRock Inc. — 9.50%
Wellington Management Group LLP — 1.28%
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC — 1.22%
Bank of America Corp DE — 1.20%
AIGH Capital Management LLC — 0.98%
Solas Capital Management LLC — 0.74%
Learn More about top institutional investors of Vertex Pharmaceuticals stock.
Which major investors are selling Vertex Pharmaceuticals stock?: Within the previous quarter, VRTX stock was sold by these institutional investors:
B. Metzler seel. Sohn & Co. AG
HighTower Advisors LLC
Allworth Financial LP
Royal London Asset Management Ltd.
Engineers Gate Manager LP
Strategic Advisors LLC
Baird Financial Group Inc.
Washington Trust Bank
In the last year, company insiders that have sold Vertex Pharmaceuticals company stock include:
Amit Sachdev (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (EVP)
Carmen Bozic (CMO)
Jeffrey M Leiden (Chairman)
Edward Morrow Atkinson III (EVP)
Joy Liu (EVP)
Jonathan Biller (EVP)
Duncan Mckechnie (EVP)
Mark E Bunnage (EVP)
Kristen Ambrose (CAO)
Sangeeta N Bhatia (Director)
Learn More investors selling Vertex Pharmaceuticals stock.
Which major investors are buying Vertex Pharmaceuticals stock?: During the previous quarter, VRTX stock was acquired by institutional investors including:
BlackRock Inc.
Bank of America Corp DE
AIGH Capital Management LLC
Solas Capital Management LLC
Legal & General Group Plc
BlackRock Inc.
Bank of New York Mellon Corp
Deutsche Bank AG